82 FR 4366 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 9 (January 13, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 9 (January 13, 2017)
| Page Range | 4366-4366 | |
| FR Document | 2017-00735 |
[Federal Register Volume 82, Number 9 (Friday, January 13, 2017)] [Notices] [Page 4366] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-00735] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Monoclonal Antibodies That Neutralize Norovirus Description of Technology: Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications:Therapeutics Diagnostics Competitive Advantages: There are currently no vaccines or therapeutics available against Norovirus infections Development Stage: In vivo data available (animal) Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, Stanislav Sosnovtsev, Karin Bok (all from NIAID). Publications: Chen Z, et al., Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis, J Virol. 2013 Sep; 87(17):9547-57. [PMID 23785216]. Intellectual Property: HHS Reference No. E-226-2011/0--U.S. Provisional Application No. 61/763,879, filed February 12, 2013; PCT Application No. PCT/US2014/015809, filed February 11, 2014; European Application No. 14706239.2, filed August 5, 2015 (pending); U.S. Application No. 14/767,274, filed August 11, 2015 (allowed); and U.S. Application No. 15/359,438, filed November 22, 2016 (pending). Licensing Contact: Dr. Jenish Patel, 240-669-2894; [email protected]. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic or a diagnostic for Norovirus infections. For collaboration opportunities, please contact Dr. Jenish Patel, 240-669-2894; [email protected]. Dated: January 9, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017-00735 Filed 1-12-17; 8:45 am] BILLING CODE 4140-01-P
![4366 Federal Register / Vol. 82, No. 9 / Friday, January 13, 2017 / Notices
NIH_Guidelines.html), these DEPARTMENT OF HEALTH AND development and evaluation under a
experiments can proceed only after they HUMAN SERVICES research collaboration.
are reviewed by the NIH Recombinant Potential Commercial Applications:
DNA Advisory Committee (RAC) and National Institutes of Health • Therapeutics
specifically approved by the NIH • Diagnostics
Director as Major Actions. This proposal Government-Owned Inventions; Competitive Advantages:
was discussed at the December 4, 2015, Availability for Licensing
• There are currently no vaccines or
RAC meeting. The proposal was AGENCY: National Institutes of Health, therapeutics available against
published in the Federal Register on HHS. Norovirus infections
December 29, 2015, (80 FR 81346) with Development Stage:
ACTION: Notice.
a request for public comment; one
comment was received. This notice • In vivo data available (animal)
SUMMARY: The invention listed below is
announces the final NIH action Inventors: Zhaochun Chen, Robert H.
owned by an agency of the U.S.
regarding this proposal. Purcell, Lisbeth Kim Green, Stanislav
Government and is available for
FOR FURTHER INFORMATION CONTACT: If Sosnovtsev, Karin Bok (all from NIAID).
licensing to achieve expeditious
you have questions, or require Publications: Chen Z, et al.,
commercialization of results of
additional background information Development of Norwalk virus-specific
federally-funded research and
about this action, please contact the NIH monoclonal antibodies with therapeutic
development. Foreign patent
by email at SciencePolicy@od.nih.gov, potential for the treatment of Norwalk
applications are filed on selected
or by telephone at 301–496–9838 and virus gastroenteritis, J Virol. 2013 Sep;
inventions to extend market coverage
reference this notice. 87(17):9547–57. [PMID 23785216].
for companies and may also be available Intellectual Property: HHS Reference
SUPPLEMENTARY INFORMATION: This final for licensing. No. E–226–2011/0—U.S. Provisional
action does not allow an investigator at FOR FURTHER INFORMATION CONTACT: Application No. 61/763,879, filed
the University of Chicago to transfer Licensing information and copies of the February 12, 2013; PCT Application No.
chloramphenicol resistance to three patent applications listed below may be PCT/US2014/015809, filed February 11,
different Rickettsia species: Rickettsia obtained by communicating with the 2014; European Application No.
typhi, rickettsii, and felis. The indicated licensing contact at the 14706239.2, filed August 5, 2015
investigator also proposed to transfer Technology Transfer and Intellectual (pending); U.S. Application No. 14/
chloramphenicol resistance to a fourth Property Office, National Institute of 767,274, filed August 11, 2015
Rickettsia species, R. conorii. Transfer of Allergy and Infectious Diseases, 5601 (allowed); and U.S. Application No. 15/
chloramphenicol resistance to R. conorii Fishers Lane, Rockville, MD 20852; tel. 359,438, filed November 22, 2016
was previously approved by the NIH 301–496–2644. A signed Confidential (pending).
Director as a Major Action (see 73 FR Disclosure Agreement will be required Licensing Contact: Dr. Jenish Patel,
32719) and therefore did not need to be to receive copies of unpublished patent 240–669–2894; Jenish.Patel@nih.gov.
reviewed and approved under Section applications. Collaborative Research Opportunity:
III–A–1–a of the NIH Guidelines. Thus, The National Institute of Allergy and
SUPPLEMENTARY INFORMATION:
the University of Chicago investigator Infectious Diseases is seeking statements
Technology description follows.
was allowed to proceed with the of capability or interest from parties
transfer of chloramphenicol resistance Monoclonal Antibodies That Neutralize
interested in collaborative research to
to R. conorii under Section III–B–2 of Norovirus
further develop, evaluate or
the NIH Guidelines. Description of Technology: Vaccines
The proposal to transfer commercialize for development of a
and therapies to prevent and treat therapeutic or a diagnostic for Norovirus
chloramphenicol resistance to R. typhi,
Norovirus infections do not exist, infections. For collaboration
rickettsii, and felis was discussed with
despite the worldwide prevalence of opportunities, please contact Dr. Jenish
a working group of the RAC via a
Norovirus infections. Outbreaks of Patel, 240–669–2894; Jenish.Patel@
teleconference call on October 22, 2015.
human gastroenteritis attributable to nih.gov.
The recommendations of this group
Norovirus commonly occur in group Dated: January 9, 2017.
were presented to and discussed with
setting, such as hospitals, nursing
the RAC at its December 4, 2015, Suzanne Frisbie,
homes, schools, dormitories, cruise
meeting. At the March 8, 2016, meeting, Deputy Director, Technology Transfer and
ships and military barracks. This
the RAC continued the discussion Intellectual Property Office, National Institute
which included consideration of the one technology relates to chimpanzee- of Allergy and Infectious Diseases.
comment received to the December 29, human chimeric monoclonal antibodies,
[FR Doc. 2017–00735 Filed 1–12–17; 8:45 am]
2015, notice and unanimously which specifically bind to Norovirus
BILLING CODE 4140–01–P
recommended (by a vote of 11 in favor, and have therapeutic potential. The
none opposed, and no abstentions) that antibodies that were tested in a primate
the transfer of chloramphenicol model of infection have shown DEPARTMENT OF HEALTH AND
resistance to R. typhi, rickettsii, and felis protection against Norovirus. These HUMAN SERVICES
should not be allowed to proceed. On Norovirus antibodies may have
August 23, 2016, the NIH Director application as immunoprophylaxis to National Institutes of Health
protect individuals from infections or as
asabaliauskas on DSK3SPTVN1PROD with NOTICES
disapproved the proposal to transfer
chloramphenicol resistance to R. typhi, a possible treatment for infected National Institute of Diabetes and
rickettsii, and felis. individuals, or can be used to develop Digestive and Kidney Diseases; Notice
a diagnostic for detection of norovirus of Closed Meetings
Dated: January 6, 2017. infections.
Francis S. Collins, This technology is available for Pursuant to section 10(d) of the
Director, National Institutes of Health. licensing for commercial development Federal Advisory Committee Act, as
[FR Doc. 2017–00766 Filed 1–12–17; 8:45 am] in accordance with 35 U.S.C. 209 and 37 amended (5 U.S.C. App.), notice is
BILLING CODE 4140–01–P CFR part 404, as well as for further hereby given of the following meetings.
VerDate Sep<11>2014 19:06 Jan 12, 2017 Jkt 241001 PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 E:\FR\FM\13JAN1.SGM 13JAN1](https://thefederalregister.org/doc/82_FR_4375/page/1.svg)
Document Created: 2017-01-13 02:45:18
Document Modified: 2017-01-13 02:45:18
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. | |
| FR Citation | 82 FR 4366 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR